What's happening
This bill establishes an endocannabinoid system awareness program and work group to educate health professionals and the public about the system and its role in health.
Why it matters
Mandates Comprehensive Training for Health Professionals. The bill requires all licensed health care practitioners (and new licensees/residents) to complete three hours of state-approved training on the endocannabinoid system every three years, integrating this topic into ongoing professional education and potentially shaping how providers approach pain management, addiction, and patient care.
Broad and Specific Educational Scope. The required curriculum covers detailed scientific, clinical, and pharmacological aspects of the endocannabinoid system, cannabinoids, chronic pain, opioids, pharmacogenetics, and FDA-approved cannabinoid medications—signaling a shift toward more nuanced, science-based understanding of cannabis and related therapies among New York’s health workforce.
Creates a State Work Group for Public and Professional Outreach. The bill establishes a diverse expert work group tasked with developing educational resources, recommending model courses, and launching a public awareness campaign—potentially leading to more informed public discourse, reduced stigma, and better patient-provider communication around cannabis and endocannabinoid health.
Builds a Feedback and Oversight Loop. By requiring regular reporting to state leadership and allowing for ongoing updates to the work group’s membership and focus areas, the bill ensures the program can adapt to evolving research, clinical practices, and public health needs—positioning New York as a leader in integrating endocannabinoid science into mainstream healthcare and public awareness.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Title VIII licensees and medical residents
The bill would require three hours of approved endocannabinoid system training every three years, with completion attestations and exemptions for demonstrated lack of need or equivalent training.
Department of Health
The department would oversee training standards and approvals, administer exemptions, establish an expert work group and publish public awareness materials.
State Education Department and Office of Cannabis Management
Both agencies would be consulted on training standards and course approvals.
Pharmacists, pharmacies and consumer advisory organizations
These groups would be represented on a work group developing education recommendations, training materials and a public awareness campaign about the endocannabinoid system.
Headline styles
Require Cannabis System Training
Plain English, a few words. Used as the page title.
Sponsors
1 Co-sponsor
History
- Referred to health
Full text
4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
10001
IN ASSEMBLY
May 1, 2024
Introduced by M. of A. KELLES -- read once and referred to the Committee on Health
AN ACT to amend the public health law, in relation to establishing the endocannabinoid system awareness program
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new section 3309-c to read as follows:
§ 3309-c. Endocannabinoid system awareness program. 1. There is hereby established within the department the endocannabinoid system awareness program which shall educate health care practitioners regarding the endocannabinoid system and how it interacts with other bodily systems.
2. The commissioner, in consultation with the department of education and the office of cannabis management, shall establish standards, review and approve course work or training on the endocannabinoid system, and publish information related to such standards, course work or training on the department's website. The commissioner, the department of education and the office of cannabis management may consider existing course work or training, including course work or training developed by a nationally recognized health care professional, specialty, provider association or nationally recognized pain management association, when establishing such standards and reviewing or approving such course work or training.
3. The commissioner shall set the following minimum hours of course work and training required to satisfactorily meet the criteria established pursuant to subdivision two of this section:
(a) every person licensed under title eight of the education law shall on or before July first, two thousand twenty-five and once every three years thereafter, complete three hours of course work or training on the endocannabinoid system which has been approved by the department.
(b) every person who shall receive a license on or after July first, two thousand twenty-five under title eight of the education law, and every medical resident, shall complete such course work or training
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD14857-01-4
within one year of gaining such status and once every three years thereafter.
4. The commission shall consider the following course work or training topics as satisfactorily meeting the training standards established pursuant to subdivision two of this section and shall include the following topics and accompanying subtopics:
(a) the endocannabinoid system, including the following subtopics:
(i) the history of tetrahydrocannabinol (THC) pharmacology;
(ii) the clinical effects of the endocannabinoid system;
(iii) limitations of available research on the endocannabinoid system;
(iv) understanding how the endocannabinoid system is dependent on lipid-based pharmacokinetics and pharmacodynamics;
(v) the components of the endocannabinoid system;
(vi) specific enzymes used by the endocannabinoid system;
(vii) ligands of the endocannabinoid system receptors;
(viii) ligands of the CB1 and CB2 receptors;
(ix) dynamics of the endocannabinoid system receptor expression;
(x) the location and function of CB1 receptors, and how such receptors express themselves in bodily systems;
(xi) specific immune system functions of the endocannabinoid system; and
(xii) specific physiologic functions related to the endocannabinoid system;
(b) cannabinoids, chronic pain and opioids, including the following subtopics:
(i) comparisons between the efficiency of non-opioid and opioid drugs for chronic back pain;
(ii) the magnitude of the prescription opioid overdose epidemic;
(iii) how concomitant use of opioids and benzodiazepines have adverse impacts on health;
(iv) the mechanisms by which cannabinoids impact the nociception system and spasticity;
(v) receptors involved with cannabinoid effects on pain modulation;
(vi) general safety and adverse effects between opioids, non-steroidal anti-inflammatory drugs, and cannabinoids;
(vii) common conditions in which medical cannabis should be recommended;
(viii) negative side effects opioid sparing helps reduce;
(ix) the addition of cannabinoid medication to chronic opioid therapy; and
(x) which form of cannabis a patient should use when tapering from a slow-release opioid;
(c) pharmacogenetics and cannabis, including the following subtopics:
(i) how to identify patient access issues and strategies on how to explain pharmacogenetics are no longer as expensive;
(ii) description of the variation of alleles;
(iii) identifying the principal organ responsible for metabolizing medications;
(iv) the importance of how THC is metabolized;
(v) how cannabinoids act as drug metabolizing enzymes;
(vi) how cytochrome P450 (CYP) monooxygenases enzymes interact with a comprehensive metabolic panel and the liver;
(vii) how to interpret genotype information for patient care;
(viii) the clinical application of cannabis with opioids;
(ix) which clinical conditions support the need for propoxyphene testing;
(x) the potential risk of cannabis dependency; and
(xi) the history of psychosis induced by THC use; and
(d) food and drug administration (FDA) approved cannabinoid medications, including the following subtopics:
(i) identifying the currently approved FDA cannabinoid drugs;
(ii) the history behind the first synthetic THC medications originally approved by the FDA to treat clinical conditions;
(iii) the clinical conditions for which the FDA approved the plant extract isolate of CBD;
(iv) the two thousand seventeen report by the national academies of sciences on the clinical use of cannabinoids;
(v) pharmacokinetics of nabilone and THC analogues such as dronabinol;
(vi) conditions that dronabinol have been used for that are not FDA approved and common side effects; and
(vii) education on how nabiximols are administered.
5. Every person licensed or in the process of being licensed pursuant to subdivision three of this section shall attest to the department that such licensed person or person in the process of being licensed shall have completed the necessary course work or training required by this section on a form prescribed by the commissioner.
6. The department shall establish a procedure for allowing licensees an exemption from the requirements of this section if any licensed person establishes that:
(a) the licensed person or person in the process of being licensed clearly demonstrates to the department's satisfaction that there would be no need for such licensed person to complete such course work or training; or
(b) the licensed person or person in the process of being licensed completed course work or training deemed by the department to be equivalent to the course work or training approved by the department pursuant to subdivision two of this section.
7. Nothing in this section shall preclude such course work or training about the endocannabinoid system from counting toward the continuing education requirements under title eight of the education law or the continuing requirements of a nationally accredited medical board to the extent acceptable to such board.
§ 2. The public health law is amended by adding a new section 3309-d to read as follows:
§ 3309-d. Endocannabinoid system work group for public awareness. 1. The commissioner of public health shall establish an endocannabinoid system work group (referred to in this section as the "work group"). Such work group shall be established no later than one year after the effective date of this section. Such work group shall be composed of experts with significant knowledge and expertise related to the endocannabinoid system, and shall include, but not be limited to, consumer advisory organizations, health care practitioners and providers, and pharmacists and pharmacies. Members of such work group shall receive no compensation for their services but shall be allowed the actual and necessary expenses in the performance of their duties pursuant to this section.
2. The work group shall report to the commissioner regarding the development of recommendations and model courses for continuing medical education, refresher courses, and other training materials for licensed health care professionals related to the endocannabinoid system and continuing education requirements for pharmacists related to the endocannabinoid system. Such recommendations, model courses, and other training materials shall be submitted to the commissioner, who shall make such information available for use in medical education, residency programs, fellowship programs, and in continuing medication education programs no later than January first, two years after the effective date of this section.
3. No later than January first, two years after the effective date of this section, the work group shall provide outreach and assistance to health care professional organizations to encourage and facilitate continuing medical education training programs for their members related to the endocannabinoid system.
4. On or before September first, one year after the effective date of this section, the commissioner of health, in consultation with the office of cannabis management, the commissioner of the department of education, and the executive secretary of the state board of pharmacy, shall have the authority to add additional members to the work group as appropriate to provide guidance in furtherance of the implementation of the work group's efforts.
5. The work group shall be responsible for developing a public awareness campaign to be provided to the commissioner of health, such public awareness campaign shall include information and resources about the endocannabinoid system and be available on the department of health's website with active weblinks to materials for the public to access.
6. The commissioner shall have the power to direct the work group to consider and research any issue on the endocannabinoid system deemed relevant under their discretion.
7. The commissioner shall report to the governor, the temporary president of the senate and the speaker of the assembly no later than two years after the effective date of this section and annually thereafter on the work group's findings in regard to its continuing education efforts, the status of the public awareness campaign, and any other issues deemed relevant by the commissioner on the endocannabinoid system.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.